Overview

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Status:
Completed

Trial end date:
2021-07-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Phase:

Phase 2

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator:

Foundation Medicine

Treatments:

Rucaparib